Vertex Pharmaceuticals Incorporated Common Stock (VRTX)
Stock · NASDAQ · Health Care
$541.72as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$433.95
Industry
Biotechnology: Pharmaceutical Preparations
About VRTX
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Website
- www.vrtx.com/
Fundamentals
- Market cap
- $122.68B
- P/E (trailing)
- 30.70
- P/E (forward)
- —
- EPS (trailing)
- $17.19
- Dividend yield
- —
- Beta
- 0.27
- Avg. volume
- —
52-week range
$374.17$555.69
How Vertex Pharmaceuticals Incorporated Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 13, 2026 · via SEC EDGAR / Finnhub
Vertex Pharmaceuticals Incorporated Common Stock Competitors
Chosen by industry and closest market cap.
- VRTXVertex Pharmaceuticals Incorporated Common Stock$541.72▼ 1.06%Market cap $122.68BP/E 30.70$374.17$555.69
- GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)$50.82▲ 1.09%Market cap $105.65BP/E 15.53$1,441$2,282
- SNYSanofi ADS$44.82▼ 0.04%Market cap $104.60BP/E 16.24$71.25$91.15
- PFEPfizer Inc. Common Stock$27.95▼ 0.25%Market cap $149.33BP/E 35.19$23.58$28.75
- REGNRegeneron Pharmaceuticals Inc. Common Stock$793.96▼ 1.70%Market cap $79.49BP/E 18.98$541$847
- ABTAbbott Laboratories Common Stock$112.42▲ 0.74%Market cap $186.81BP/E 35.52$81.97$137.49
- TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)$18.04▲ 0.06%Market cap $53.78BP/E —$4,102$6,033
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated Common Stock | $122.68B | 30.70 | $541.72 | ▼ 1.06% | $374.17$555.69 |
| GSK GSK plc American Depositary Shares (Each representing two Ordinary Shares) | $105.65B | 15.53 | $50.82 | ▲ 1.09% | $1,441$2,282 |
| SNY Sanofi ADS | $104.60B | 16.24 | $44.82 | ▼ 0.04% | $71.25$91.15 |
| PFE Pfizer Inc. Common Stock | $149.33B | 35.19 | $27.95 | ▼ 0.25% | $23.58$28.75 |
| REGN Regeneron Pharmaceuticals Inc. Common Stock | $79.49B | 18.98 | $793.96 | ▼ 1.70% | $541$847 |
| ABT Abbott Laboratories Common Stock | $186.81B | 35.52 | $112.42 | ▲ 0.74% | $81.97$137.49 |
| TAK Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | $53.78B | — | $18.04 | ▲ 0.06% | $4,102$6,033 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Todaybenzinga · 8/27/2026
- Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’Benzinga · 8/21/2026
- Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still AheadYahoo · 8/20/2026
- Are Wall Street Analysts Bullish on Vertex Stock?Yahoo · 8/20/2026
- HEALWELL AI's DARWEN(TM) AI Platform Nominated for 2026 International Prix Galien, the Global "Best of the Best" in Life Sciences InnovationYahoo · 8/19/2026
- Vortex Energy Announces Final Ambient Noise Tomography Results for the Robinsons River Salt ProjectYahoo · 8/18/2026
- 3 Cash-Producing Stocks on Our WatchlistYahoo · 8/18/2026
- Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?Yahoo · 8/14/2026
- Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?Yahoo · 8/14/2026
Insider Activity
Insider Actions →Acquired
16.6K
Disposed
18.1K
- Ourania Tatsis · July 21, 2026 · Grant8.3K
- Amit Sachdev · July 21, 2026 · Grant8.3K
- Alan M. Garber · July 15, 2026 · Grant32 @ $475.28
- SACHS BRUCE I · July 15, 2026 · Grant100 @ $475.28
- Duncan McKechnie · July 2, 2026 · Sale1.5K @ $519
- Ourania Tatsis · July 2, 2026 · Sale1.5K @ $524.99
- Joy Liu · July 1, 2026 · Sale828 @ $502.71
- Carmen Bozic · June 18, 2026 · Sale1.0K @ $462.17
- Carmen Bozic · June 5, 2026 · Sale1.7K @ $450
- Joy Liu · June 1, 2026 · Sale828 @ $439.91
- Carmen Bozic · May 29, 2026 · Sale2.0K @ $450
- Mark E. Bunnage · May 15, 2026 · Sale33 @ $453.45
- Carmen Bozic · May 15, 2026 · Sale1.4K @ $453.45
- Carmen Bozic · May 12, 2026 · Sale7.0K @ $450
- Sangeeta N. Bhatia · May 4, 2026 · Sale318 @ $423.73
Institutional Ownership
March 31, 2026
- Total shares held
- 220.10M
- Total value held
- $95.91B
- Institutional holders
- 1663
Top holders this quarter
- Unknown25.37M
- Unknown23.97M
- Unknown21.13M
- Unknown16.51M
- Unknown11.73M
- Unknown6.14M
- Unknown5.13M
- Unknown4.00M
- Unknown3.91M
- Unknown3.21M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedSynthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
August 30, 2026
Vertex Pharmaceuticals in Spotlight as Investors Weigh Recent Rally. Vertex Pharmaceuticals has drawn attention from investors and analysts over the past week. Articles highlight the company's upcoming participation in September investor conferences, where management may address pipeline and financial outlook. Several pieces also frame Vertex within broader investment themes, comparing its long-term returns and positioning it among large-caps that some analysts view favorably during periods of rising inflation. The stock has gained roughly 15% over the past month, though it still trades below its 52-week high, and one technical signal flagged is a negative RSI divergence.